MEDICINES Company

Oct 01, 2018

Homology Medicines to Present at Upcoming Conferences

Aug 30, 2018

Homology Medicines to Participate in Gene Editing Panel at Citi's Biotech Conference

Aug 13, 2018

Homology Medicines Reports Second Quarter 2018 Financial Results

Jul 16, 2018

Homology Medicines Announces Peer-Reviewed Publication Demonstrating Efficient and Precise In Vivo Gene Editing Capabilities of Nuclease-Free Technology Platform

Jul 05, 2018

Homology Medicines to Present at the National PKU Alliance Conference

May 18, 2018

Homology Medicines Presents Data from PKU Gene Therapy Program Demonstrating Long-Term Durability of Treatment in IND-Enabling Studies

May 10, 2018

Homology Medicines to Present at Bank of America Merrill Lynch Healthcare Conference

Apr 30, 2018

Homology Medicines Announces Upcoming Presentations on its Genetic Medicines Platform at the American Society of Gene & Cell Therapy Meeting

Apr 23, 2018

Homology Medicines to Participate in the World Orphan Drug Congress

Apr 03, 2018

Homology Medicines Announces Closing of Initial Public Offering

Mar 27, 2018

Homology Medicines Announces Pricing of Initial Public Offering

Mar 15, 2018

Homology Medicines Appoints Mary Thistle to Board of Directors

Aug 01, 2017

Homology Medicines Announces $83.5 Million Series B Financing to Advance Lead Development Candidate and AMEnDR(TM) In Vivo Gene Editing Technology